echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Huahai Pharmaceutical's Metoprolol Succinate Sustained-Release Tablets and Silodosin Capsules were approved by the US FDA

    Huahai Pharmaceutical's Metoprolol Succinate Sustained-Release Tablets and Silodosin Capsules were approved by the US FDA

    • Last Update: 2022-03-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 6, Huahai Pharmaceutical issued an announcement saying that the abbreviated new drug application for metoprolol succinate sustained-release tablets and silodosin capsules submitted by the company to the US FDA has been approved
    .

    1.
    Metoprolol succinate sustained-release tablets

    1.
    Metoprolol succinate sustained-release tablets

    Metoprolol succinate extended-release tablets are mainly used for the treatment of hypertension, angina pectoris, and symptomatic stable chronic heart failure with abnormal left ventricular systolic function
    .


    Metoprolol succinate extended-release tablets were developed by AstraZeneca and first launched in 1992


    Up to now, the company has invested about 6.
    37 million yuan in research and development on the metoprolol succinate sustained-release tablet project
    .

    2.
    Silodosin Capsules

    2.
    Silodosin Capsules

    Silodosin Capsules are primarily used to improve symptoms and signs of benign prostatic hyperplasia (BHP)
    .


    Silodosin capsules were developed by Allergan and were first launched in 2008


    Up to now, the company has invested about 4.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.